

8 November 2018



Result of AGM

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, held its Annual General Meeting ("AGM") today at which all resolutions were passed.

The Board notes the voting results around two resolutions and will continue to have close dialogue with our shareholders to ensure that they and the Group are closely aligned.

At the meeting, Peter Allen, Clinigen's Chairman reiterated that the Group is well positioned to deliver another year of good progress, as set out at the recent full year results.

Full details of the poll results and the slides from the presentation given by the Group will be made available on Clinigen's website www.clinigengroup.com.

- Ends -

Clinigen Group plc

Shaun Chilton, Group Chief Executive Officer
Martin Abell, Group Chief Executive Officer
Matt Parrish, Head of Investor Relations

Tel: +44 (0) 1283 495 010

Numis Securities Limited

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)

Tel: +44 (0) 20 7260 1000

RBC Capital Markets – Joint Broker

Marcus Jackson / Elliot Thomas

Tel: +44 (0) 20 7653 4000

Instinctif Partners (media relations)

Melanie Toyne-Sewell / Alex Shaw / Deborah Bell

Tel: +44 (0) 20 7457 2020

Email: clinigen@instinctif.com

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com